Diversified healthcare company CVS Health (NYSE: CVS) reported Q2 CY2026 results exceeding the market’s revenue expectations, with sales up 7.3% year on year to $106.1 billion. Its non-GAAP profit of $2.58 per share was 39.4% above analysts’ consensus estimates.

Is now the time to buy CVS? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

CVS Health’s second quarter was marked by better-than-expected revenue and profit, but investor sentiment was dampened by rising concerns over sustainability of these results. Management cited strong performance across all business segments, particularly from specialty pharmacy and Medicare Advantage, as key drivers. CEO David Joyner acknowledged, “the cumulative impact of these actions [in Aetna and Caremark] is starting to come through clearly in our results.” However, management also highlighted pockets of pressure, such as ongoing challenges in the 340B program and the normalization of script share gains from Rite Aid.

Looking ahead, CVS Health’s raised guidance is underpinned by continued investments in technology, growth in direct-to-consumer GLP-1 offerings, and margin recovery in its insurance business. Management expects AI-powered initiatives like the Health100 platform and automation in claims processing to improve efficiency and the consumer experience. CFO Brian Newman noted, “We are making meaningful progress unlocking our embedded earnings power,” while also cautioning about 340B headwinds and potential membership declines in Caremark next year. The company’s outlook emphasizes balancing cost management with strategic growth initiatives.

Key Insights from Management’s Remarks

Management attributed Q2 outperformance to specialty pharmacy strength, disciplined cost actions in Aetna, and rapid progress in AI and consumer health platforms.

• Specialty pharmacy momentum: CVS Specialty’s adherence rates consistently exceed 90%, well above industry standards, driven by early patient identification and AI-enabled support. Management underscored this as a differentiator that supports both revenue growth and improved patient outcomes.
• GLP-1 expansion: Demand for GLP-1 therapies (weight loss drugs) continues to accelerate. CVS expanded formulary access through Caremark and launched new direct-to-consumer options via MinuteClinic and partnerships with Eli Lilly and Novo. These offerings lower barriers for both insured and cash-pay consumers, positioning CVS as a key access point for these high-profile treatments.
• Margin recovery at Aetna: The insurance segment’s improved profitability was attributed to disciplined pricing, clinical program enhancements, and a favorable member mix in Medicare Advantage. Management noted over $2 billion of year-over-year improvement in adjusted operating income in Aetna, with progress expected to continue.
• AI and technology investments: The Health100 platform and Haio assistant are designed to enhance consumer engagement, while AI-driven claims management is reducing administrative friction for providers. Management highlighted over $1 billion in operational savings from technology and AI initiatives in recent years.
• 340B and pharmacy reimbursement headwinds: Ongoing manufacturer restrictions in the 340B program and continued reimbursement pressure remain key challenges. Although these issues were offset by strength in other areas this quarter, management anticipates 340B will be a headwind in 2027, requiring further adaptation.

Drivers of Future Performance

Management’s outlook centers on margin recovery in Aetna, growth in specialty and direct-to-consumer pharmacy, and continued deployment of AI to drive efficiency.

• Aetna margin trajectory: Management expects continued margin expansion in the insurance business, particularly Medicare Advantage, supported by disciplined pricing and member mix improvements. The group Medicare Advantage renewal rate—now at 75% of the book—should support stability, while cost management remains a priority.
• Pharmacy and specialty pipeline: CVS is positioning specialty pharmacy as a growth engine, with new biosimilars and GLP-1 products expanding its pipeline. The rollout of the CVS CostVantage pricing model is expected to support more sustainable pharmacy reimbursement and help mitigate the impact of script share normalization from Rite Aid.
• Technology and 340B risks: AI-powered platforms and digital engagement are expected to improve operational efficiency and consumer experience. However, management highlighted persistent risks, including 340B program headwinds due to manufacturer restrictions and the potential for membership declines in Caremark as client contracts are renegotiated.

Catalysts in Upcoming Quarters

Looking ahead, the StockStory team will be monitoring (1) the pace of GLP-1 adoption and the expansion of consumer-facing offerings, (2) the impact of AI-driven platforms like Health100 and Haio on efficiency and consumer engagement, and (3) progress on Aetna margin recovery and group Medicare Advantage renewals. We will also be watching for updates on 340B program headwinds and Caremark membership changes as contract dynamics evolve.

CVS Health currently trades at $99.36, down from $104.42 just before the earnings. In the wake of this quarter, is it a buy or sell? The answer lies in our full research report (it’s free).

Our Favorite Stocks Right Now

WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don’t just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.

But our AI platform says the party isn’t over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+271% between June 2020 and June 2025). Find your next big winner with StockStory today.